Where is Health Technology Assessment Going?
Chrissie Fletcher, Director and Head of International Biostatistics at Amgen, talks to Helen Winsor from Pharma IQ, about innovation in clinical design, analysis and reporting. Fletcher discusses how she sees health economists and statisticians interacting going forwards, why there is so much emphasis on reporting for reimbursement and whether she expects pharma companies will try and do this more in-house, in the future. Fletcher also offers her thoughts on health economists who...
To continue reading this story
Please note: That all fields marked with an asterisk (*) are required.